Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JAGX
CUSIPN/A
Phone415-371-8300
Debt
Debt-to-Equity Ratio0.52
Current Ratio1.16
Quick Ratio0.91
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.36 million
Price / Sales3.04
Cash FlowN/A
Price / CashN/A
Book Value$2.46 per share
Price / Book0.47
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-21,960,000.00
Net Margins-527.30%
Return on Equity-116.86%
Return on Assets-46.96%
Miscellaneous
Employees36
Outstanding Shares11,430,000
Market Cap$12.57
Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions
What is Jaguar Health's stock symbol?
Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."
How were Jaguar Health's earnings last quarter?
Jaguar Health Inc (NASDAQ:JAGX) announced its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.75) earnings per share for the quarter. The biotechnology company had revenue of $0.80 million for the quarter. Jaguar Health had a negative return on equity of 116.86% and a negative net margin of 527.30%. View Jaguar Health's Earnings History.
What is the consensus analysts' recommendation for Jaguar Health?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Jaguar Health's key competitors?
Some companies that are related to Jaguar Health include Imprimis Pharmaceuticals (IMMY), vTv Therapeutics (VTVT), Heat Biologics (HTBX), Moleculin Biotech (MBRX), AzurRx BioPharma (AZRX), Avenue Therapeutics (ATXI), Acerus Pharmaceuticals (TRLPF), Evoke Pharma (EVOK), Capricor Therapeutics (CAPR), Onconova Therapeutics (ONTX), Chiasma (CHMA), Tonix Pharmaceuticals (TNXP), PLx Pharma (PLXP), Q BioMed (QBIO) and ProPhase Labs (PRPH).
Who are Jaguar Health's key executives?
Jaguar Health's management team includes the folowing people:
- Ms. Lisa A. Conte, CEO, Pres & Director (Age 59)
- Ms. Karen S. Wright, CFO & Treasurer (Age 62)
- Dr. Steven R. King, Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 60)
- Dr. Pravin R. Chaturvedi, Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 55)
- Mr. Pete Riojas, National Sales Director
When did Jaguar Health IPO?
(JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.
Has Jaguar Health been receiving favorable news coverage?
Press coverage about JAGX stock has trended somewhat positive on Friday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Jaguar Health earned a media sentiment score of 0.21 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.01 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Jaguar Health's major shareholders?
Jaguar Health's stock is owned by many different of retail and institutional investors. Top institutional investors include NANTUCKET INVESTMENTS LTD (16.06%). Company insiders that own Jaguar Health stock include Jonathan B Siegel and Lisa A Conte. View Institutional Ownership Trends for Jaguar Health.
How do I buy shares of Jaguar Health?
Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jaguar Health's stock price today?
One share of JAGX stock can currently be purchased for approximately $1.16.
How big of a company is Jaguar Health?
Jaguar Health has a market capitalization of $12.57 million and generates $4.36 million in revenue each year. Jaguar Health employs 36 workers across the globe.
How can I contact Jaguar Health?
Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.
MarketBeat Community Rating for Jaguar Health (NASDAQ JAGX)
MarketBeat's community ratings are surveys of what our community members think about Jaguar Health and other stocks. Vote "Outperform" if you believe JAGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
